Medical condition
Biosimilars
Biosimilars is a medical condition tracked by NovaPharmaNews. Browse the latest pharmaceutical industry coverage and developments.
Latest Biosimilars news
FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria
The FDA approved Immgolis and Immgolis Intri as the first interchangeable biosimilars to Janssen’s Simponi and Simponi Aria. The decision covers rheumatoid arthritis and ulcerative colitis and creates a new catalyst for BD teams and investors tracking golimumab competition.
Biosimilars Drive Significant Reductions in Specialty Drug Spending
Biosimilars are poised to significantly reduce specialty drug expenditures, with projections indicating potential savings of up to 20%. This analysis explores the market impact, patient cost benefits, and strategic implications for the pharmaceutical industry.
Biosimilars Growth in Brazil: Market Potential Post-ANVISA Regulatory Updates
This article delves into the market potential for biosimilars in Brazil following recent ANVISA regulatory updates, highlighting Infliximab's role in treating autoimmune conditions.
Biosimilars Market Analysis: US Landscape Post-Inflation Reduction Act 2026
This article analyzes the evolving landscape of the US biosimilars market for Humira post-Inflation Reduction Act 2026, highlighting key trends and implications.
Biosimilars Market Analysis: Impact of Recent FDA Approvals on US Pricing & Competition
This article analyzes how recent FDA approvals of biosimilars are reshaping pricing dynamics and competition in the US pharmaceutical market.
Rise of Biosimilars in US: FDA Approval Trends & Market Impact
The article delves into the growing presence of biosimilars in the US market, focusing on FDA approval trends and their implications for drug pricing and patient access.
SAHPRA Biosimilars Approval: Pathway Analysis & Impact on Affordable Medicines
This article analyzes SAHPRA's biosimilars approval pathway and its significant impact on making affordable medicines like adalimumab accessible for patients.
Rise of Biosimilars: Market Impact Post-2026 Patent Expirations in US
As key biologics like Herceptin face patent expirations post-2026, the rise of biosimilars is set to transform the US pharmaceutical landscape.